

Xuping Xie

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7620789/publications.pdf>

Version: 2024-02-01

107
papers

14,181
citations

34076

52
h-index

30058

103
g-index

154
all docs

154
docs citations

154
times ranked

18641
citing authors

#	ARTICLE	IF	CITATIONS
1	Spike mutation D614G alters SARS-CoV-2 fitness. <i>Nature</i> , 2021, 592, 116-121.	13.7	1,380
2	Resistance of SARS-CoV-2 variants to neutralization by monoclonal and serum-derived polyclonal antibodies. <i>Nature Medicine</i> , 2021, 27, 717-726.	15.2	838
3	Evasion of Type I Interferon by SARS-CoV-2. <i>Cell Reports</i> , 2020, 33, 108234.	2.9	742
4	An Infectious cDNA Clone of SARS-CoV-2. <i>Cell Host and Microbe</i> , 2020, 27, 841-848.e3.	5.1	617
5	SARS-CoV-2 mRNA vaccines induce persistent human germinal centre responses. <i>Nature</i> , 2021, 596, 109-113.	13.7	586
6	Loss of furin cleavage site attenuates SARS-CoV-2 pathogenesis. <i>Nature</i> , 2021, 591, 293-299.	13.7	579
7	Neutralization of SARS-CoV-2 spike 69/70 deletion, E484K and N501Y variants by BNT162b2 vaccine-elicited sera. <i>Nature Medicine</i> , 2021, 27, 620-621.	15.2	562
8	Neutralizing Activity of BNT162b2-Elicited Serum. <i>New England Journal of Medicine</i> , 2021, 384, 1466-1468.	13.9	528
9	The N501Y spike substitution enhances SARS-CoV-2 infection and transmission. <i>Nature</i> , 2022, 602, 294-299.	13.7	364
10	SARS-CoV-2 Neutralization with BNT162b2 Vaccine Dose 3. <i>New England Journal of Medicine</i> , 2021, 385, 1627-1629.	13.9	346
11	BNT162b2-elicited neutralization of B.1.617 and other SARS-CoV-2 variants. <i>Nature</i> , 2021, 596, 273-275.	13.7	318
12	A high-throughput neutralizing antibody assay for COVID-19 diagnosis and vaccine evaluation. <i>Nature Communications</i> , 2020, 11, 4059.	5.8	266
13	An Infectious cDNA Clone of Zika Virus to Study Viral Virulence, Mosquito Transmission, and Antiviral Inhibitors. <i>Cell Host and Microbe</i> , 2016, 19, 891-900.	5.1	252
14	A live-attenuated Zika virus vaccine candidate induces sterilizing immunity in mouse models. <i>Nature Medicine</i> , 2017, 23, 763-767.	15.2	242
15	Genetic and structural basis for SARS-CoV-2 variant neutralization by a two-antibody cocktail. <i>Nature Microbiology</i> , 2021, 6, 1233-1244.	5.9	237
16	An evolutionary NS1 mutation enhances Zika virus evasion of host interferon induction. <i>Nature Communications</i> , 2018, 9, 414.	5.8	231
17	In vivo monoclonal antibody efficacy against SARS-CoV-2 variant strains. <i>Nature</i> , 2021, 596, 103-108.	13.7	222
18	Delta spike P681R mutation enhances SARS-CoV-2 fitness over Alpha variant. <i>Cell Reports</i> , 2022, 39, 110829.	2.9	214

#	ARTICLE	IF	CITATIONS
19	Zika virus produces noncoding RNAs using a multi-pseudoknot structure that confounds a cellular exonuclease. <i>Science</i> , 2016, 354, 1148-1152.	6.0	212
20	A nanoluciferase SARS-CoV-2 for rapid neutralization testing and screening of anti-infective drugs for COVID-19. <i>Nature Communications</i> , 2020, 11, 5214.	5.8	179
21	Membrane Topology and Function of Dengue Virus NS2A Protein. <i>Journal of Virology</i> , 2013, 87, 4609-4622.	1.5	162
22	Molecular determinants and mechanism for antibody cocktail preventing SARS-CoV-2 escape. <i>Nature Communications</i> , 2021, 12, 469.	5.8	148
23	Engineering SARS-CoV-2 using a reverse genetic system. <i>Nature Protocols</i> , 2021, 16, 1761-1784.	5.5	137
24	Inhibition of Dengue Virus by Targeting Viral NS4B Protein. <i>Journal of Virology</i> , 2011, 85, 11183-11195.	1.5	130
25	Nasal delivery of an IgM offers broad protection from SARS-CoV-2 variants. <i>Nature</i> , 2021, 595, 718-723.	13.7	128
26	A single-dose live-attenuated vaccine prevents Zika virus pregnancy transmission and testis damage. <i>Nature Communications</i> , 2017, 8, 676.	5.8	125
27	Neutralizing Antibodies Against SARS-CoV-2 Variants After Infection and Vaccination. <i>JAMA - Journal of the American Medical Association</i> , 2021, 325, 1896.	3.8	125
28	SARS-CoV-2 Infects Human Engineered Heart Tissues and Models COVID-19 Myocarditis. <i>JACC Basic To Translational Science</i> , 2021, 6, 331-345.	1.9	121
29	Functional Analysis of Glycosylation of Zika Virus Envelope Protein. <i>Cell Reports</i> , 2017, 21, 1180-1190.	2.9	118
30	Defining the risk of SARS-CoV-2 variants on immune protection. <i>Nature</i> , 2022, 605, 640-652.	13.7	117
31	Characterization of Dengue Virus NS4A and NS4B Protein Interaction. <i>Journal of Virology</i> , 2015, 89, 3455-3470.	1.5	116
32	BNT162b2-Elicited Neutralization against New SARS-CoV-2 Spike Variants. <i>New England Journal of Medicine</i> , 2021, 385, 472-474.	13.9	93
33	Neutralization against Omicron SARS-CoV-2 from previous non-Omicron infection. <i>Nature Communications</i> , 2022, 13, 852.	5.8	92
34	Two Distinct Sets of NS2A Molecules Are Responsible for Dengue Virus RNA Synthesis and Virion Assembly. <i>Journal of Virology</i> , 2015, 89, 1298-1313.	1.5	90
35	Axl Promotes Zika Virus Entry and Modulates the Antiviral State of Human Sertoli Cells. <i>MBio</i> , 2019, 10, .	1.8	88
36	Nucleocapsid mutations in SARS-CoV-2 augment replication and pathogenesis. <i>PLoS Pathogens</i> , 2022, 18, e1010627.	2.1	85

#	ARTICLE	IF	CITATIONS
37	Mapping the Interactions between the NS4B and NS3 Proteins of Dengue Virus. <i>Journal of Virology</i> , 2015, 89, 3471-3483.	1.5	83
38	A Multiplex Microsphere Immunoassay for Zika Virus Diagnosis. <i>EBioMedicine</i> , 2017, 16, 136-140.	2.7	83
39	Envelope protein ubiquitination drives entry and pathogenesis of Zika virus. <i>Nature</i> , 2020, 585, 414-419.	13.7	82
40	Rational Design of a Flavivirus Vaccine by Abolishing Viral RNA 2'â€²- <i>O</i> Methylation. <i>Journal of Virology</i> , 2013, 87, 5812-5819.	1.5	81
41	Zika Virus Vaccine: Progress and Challenges. <i>Cell Host and Microbe</i> , 2018, 24, 12-17.	5.1	81
42	Neutralization and durability of 2 or 3 doses of the BNT162b2 vaccine against Omicron SARS-CoV-2. <i>Cell Host and Microbe</i> , 2022, 30, 485-488.e3.	5.1	80
43	Dimerization of Flavivirus NS4B Protein. <i>Journal of Virology</i> , 2014, 88, 3379-3391.	1.5	77
44	Zika Virus Replicons for Drug Discovery. <i>EBioMedicine</i> , 2016, 12, 156-160.	2.7	77
45	Zika Virus: Diagnosis, Therapeutics, and Vaccine. <i>ACS Infectious Diseases</i> , 2016, 2, 170-172.	1.8	76
46	Understanding Zika Virus Stability and Developing a Chimeric Vaccine through Functional Analysis. <i>MBio</i> , 2017, 8, .	1.8	76
47	Treatment of Human Glioblastoma with a Live Attenuated Zika Virus Vaccine Candidate. <i>MBio</i> , 2018, 9, .	1.8	74
48	A Single Amino Acid in Nonstructural Protein NS4B Confers Virulence to Dengue Virus in AG129 Mice through Enhancement of Viral RNA Synthesis. <i>Journal of Virology</i> , 2011, 85, 7775-7787.	1.5	73
49	Targeting dengue virus NS4B protein for drug discovery. <i>Antiviral Research</i> , 2015, 118, 39-45.	1.9	69
50	Dengue NS2A Protein Orchestrates Virus Assembly. <i>Cell Host and Microbe</i> , 2019, 26, 606-622.e8.	5.1	68
51	Inhibition of Coronavirus Entry <i>In Vitro</i> and <i>Ex Vivo</i> by a Lipid-Conjugated Peptide Derived from the SARS-CoV-2 Spike Glycoprotein HRC Domain. <i>MBio</i> , 2020, 11, .	1.8	63
52	Neutralization of Omicron BA.1, BA.2, and BA.3 SARS-CoV-2 by 3 doses of BNT162b2 vaccine. <i>Nature Communications</i> , 2022, 13, .	5.8	63
53	RPLP1 and RPLP2 Are Essential Flavivirus Host Factors That Promote Early Viral Protein Accumulation. <i>Journal of Virology</i> , 2017, 91, .	1.5	60
54	A Rapid Zika Diagnostic Assay to Measure Neutralizing Antibodies in Patients. <i>EBioMedicine</i> , 2017, 17, 157-162.	2.7	58

#	ARTICLE	IF	CITATIONS
55	Mouse-adapted SARS-CoV-2 protects animals from lethal SARS-CoV challenge. <i>PLoS Biology</i> , 2021, 19, e3001284.	2.6	54
56	A Zika virus envelope mutation preceding the 2015 epidemic enhances virulence and fitness for transmission. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2020, 117, 20190-20197.	3.3	53
57	Zika Virus NS2A-Mediated Virion Assembly. <i>MBio</i> , 2019, 10, .	1.8	51
58	A trans-complementation system for SARS-CoV-2 recapitulates authentic viral replication without virulence. <i>Cell</i> , 2021, 184, 2229-2238.e13.	13.5	51
59	Determinants of Dengue Virus NS4A Protein Oligomerization. <i>Journal of Virology</i> , 2015, 89, 6171-6183.	1.5	48
60	A Single-Dose Live-Attenuated Zika Virus Vaccine with Controlled Infection Rounds that Protects against Vertical Transmission. <i>Cell Host and Microbe</i> , 2018, 24, 487-499.e5.	5.1	46
61	A cDNA Clone-Launched Platform for High-Yield Production of Inactivated Zika Vaccine. <i>EBioMedicine</i> , 2017, 17, 145-156.	2.7	39
62	Remdesivir and GS-441524 Retain Antiviral Activity against Delta, Omicron, and Other Emergent SARS-CoV-2 Variants. <i>Antimicrobial Agents and Chemotherapy</i> , 2022, 66, e0022222.	1.4	39
63	Fragile X mental retardation protein is a Zika virus restriction factor that is antagonized by subgenomic flaviviral RNA. <i>ELife</i> , 2018, 7, .	2.8	37
64	A single-dose plasmid-launched live-attenuated Zika vaccine induces protective immunity. <i>EBioMedicine</i> , 2018, 36, 92-102.	2.7	37
65	Key Metabolic Enzymes Involved in Remdesivir Activation in Human Lung Cells. <i>Antimicrobial Agents and Chemotherapy</i> , 2021, 65, e0060221.	1.4	37
66	The effect of SARS-CoV-2 D614G mutation on BNT162b2 vaccine-elicited neutralization. <i>Npj Vaccines</i> , 2021, 6, 44.	2.9	36
67	Ultrapotent miniproteins targeting the SARS-CoV-2 receptor-binding domain protect against infection and disease. <i>Cell Host and Microbe</i> , 2021, 29, 1151-1161.e5.	5.1	36
68	A self-amplifying mRNA SARS-CoV-2 vaccine candidate induces safe and robust protective immunity in preclinical models. <i>Molecular Therapy</i> , 2022, 30, 1897-1912.	3.7	33
69	Genetic and biochemical characterizations of Zika virus NS2A protein. <i>Emerging Microbes and Infections</i> , 2019, 8, 585-602.	3.0	32
70	Maternal vaccination and protective immunity against Zika virus vertical transmission. <i>Nature Communications</i> , 2019, 10, 5677.	5.8	32
71	Neutralization of Omicron sublineages and Deltacron SARS-CoV-2 by three doses of BNT162b2 vaccine or BA.1 infection. <i>Emerging Microbes and Infections</i> , 2022, 11, 1828-1832.	3.0	32
72	Restriction of Zika Virus by Host Innate Immunity. <i>Cell Host and Microbe</i> , 2016, 19, 566-567.	5.1	27

#	ARTICLE	IF	CITATIONS
73	Role of microglia in the dissemination of Zika virus from mother to fetal brain. <i>PLoS Neglected Tropical Diseases</i> , 2020, 14, e0008413.	1.3	27
74	A PCR amplicon-based SARS-CoV-2 replicon for antiviral evaluation. <i>Scientific Reports</i> , 2021, 11, 2229.	1.6	27
75	Design, Synthesis, and Biological Evaluation of Substituted 4,6-Dihydrospiro[[1,2,3]triazolo[4,5- <i>b</i>]pyridine-7,3-indoline]-2,5(3 <i>H</i>)-dione Analogues as Potent NS4B Inhibitors for the Treatment of Dengue Virus Infection. <i>Journal of Medicinal Chemistry</i> , 2019, 62, 7941-7960.	2.9	26
76	Small Molecules and Antibodies for Zika Therapy. <i>Journal of Infectious Diseases</i> , 2017, 216, S945-S950.	1.9	23
77	Allosteric inhibitors of the main protease of SARS-CoV-2. <i>Antiviral Research</i> , 2022, 205, 105381.	1.9	23
78	Using recombination-dependent lethal mutations to stabilize reporter flaviviruses for rapid serodiagnosis and drug discovery. <i>EBioMedicine</i> , 2020, 57, 102838.	2.7	22
79	Cross-neutralization of Omicron BA.1 against BA.2 and BA.3 SARS-CoV-2. <i>Nature Communications</i> , 2022, 13, .	5.8	22
80	A cocrystal structure of dengue capsid protein in complex of inhibitor. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2020, 117, 17992-18001.	3.3	18
81	Identifying optimal capsid duplication length for the stability of reporter flaviviruses. <i>Emerging Microbes and Infections</i> , 2020, 9, 2256-2265.	3.0	17
82	Topoisomerase III- β is required for efficient replication of positive-sense RNA viruses. <i>Antiviral Research</i> , 2020, 182, 104874.	1.9	17
83	The RNA helicase DHX16 recognizes specific viral RNA to trigger RIG-I-dependent innate antiviral immunity. <i>Cell Reports</i> , 2022, 38, 110434.	2.9	16
84	Using a Virion Assembly-Defective Dengue Virus as a Vaccine Approach. <i>Journal of Virology</i> , 2018, 92, .	1.5	13
85	Evaluation of a SARS-CoV-2 lateral flow assay using the plaque reduction neutralization test. <i>Diagnostic Microbiology and Infectious Disease</i> , 2021, 99, 115248.	0.8	13
86	Generation and characterization of mouse monoclonal antibodies against NS4B protein of dengue virus. <i>Virology</i> , 2014, 450-451, 250-257.	1.1	12
87	Reverse Genetics of Zika Virus. <i>Methods in Molecular Biology</i> , 2017, 1602, 47-58.	0.4	10
88	The arrival of SARS-CoV-2 "neutralizing antibodies in a currently available commercial immunoglobulin. <i>Journal of Allergy and Clinical Immunology</i> , 2022, 149, 1958-1959.	1.5	10
89	Potential Mechanisms for Enhanced Zika Epidemic and Disease. <i>ACS Infectious Diseases</i> , 2018, 4, 656-659.	1.8	9
90	Design, synthesis and biological evaluation of spiropyrazolopyridone derivatives as potent dengue virus inhibitors. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2020, 30, 127162.	1.0	8

#	ARTICLE	IF	CITATIONS
91	Making sense of spike D614G in SARS-CoV-2 transmission. <i>Science China Life Sciences</i> , 2021, 64, 1062-1067.	2.3	8
92	A Single-Round Infection Fluorescent SARS-CoV-2 Neutralization Test for COVID-19 Serological Testing at a Biosafety Level-2 Laboratory. <i>Viruses</i> , 2022, 14, 1211.	1.5	8
93	Inhibition of innate immune response ameliorates Zika virus-induced neurogenesis deficit in human neural stem cells. <i>PLoS Neglected Tropical Diseases</i> , 2021, 15, e0009183.	1.3	6
94	Anti-Zika virus RNAi in neural progenitor cells. <i>Cell Research</i> , 2019, 29, 261-262.	5.7	5
95	A modified porous silicon microparticle potentiates protective systemic and mucosal immunity for SARS-CoV-2 subunit vaccine. <i>Translational Research</i> , 2022, 249, 13-27.	2.2	5
96	Repurposing an HIV Drug for Zika Virus Therapy. <i>Molecular Therapy</i> , 2019, 27, 2064-2066.	3.7	4
97	BNT162b2-elicited neutralization of Delta plus, Lambda, Mu, B.1.1.519, and Theta SARS-CoV-2 variants. <i>Npj Vaccines</i> , 2022, 7, 41.	2.9	4
98	Infection Kinetics and Transmissibility of a Reanimated Dengue Virus Serotype 4 Identified Originally in Wild <i>Aedes aegypti</i> From Florida. <i>Frontiers in Microbiology</i> , 2021, 12, 734903.	1.5	3
99	Intravenous delivery of GS-441524 is efficacious in the African green monkey model of SARS-CoV-2 infection. <i>Antiviral Research</i> , 2022, 203, 105329.	1.9	2
100	A <i>Trans</i> -Complementation System for SARS-CoV-2. <i>SSRN Electronic Journal</i> , 0, , .	0.4	1
101	Dengue and Zika RNA-RNA Interactomes Reveal Virus Permissive and Restrictive Factors in Human Cells. <i>SSRN Electronic Journal</i> , 0, , .	0.4	0
102	Role of microglia in the dissemination of Zika virus from mother to fetal brain. , 2020, 14, e0008413.		0
103	Role of microglia in the dissemination of Zika virus from mother to fetal brain. , 2020, 14, e0008413.		0
104	Role of microglia in the dissemination of Zika virus from mother to fetal brain. , 2020, 14, e0008413.		0
105	Role of microglia in the dissemination of Zika virus from mother to fetal brain. , 2020, 14, e0008413.		0
106	Role of microglia in the dissemination of Zika virus from mother to fetal brain. , 2020, 14, e0008413.		0
107	Role of microglia in the dissemination of Zika virus from mother to fetal brain. , 2020, 14, e0008413.		0